AstraZeneca appoint new MD for India

pharmafile | July 7, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, India 

AstraZeneca announced a new Managing Director for AstraZeneca Pharma India, with Gagan Singh Bedi beginning the role on 3 July. The move came after former MD Sanjay Murdeshwar resigned his position to move to take on a global role based in the US.

Singh has worked at AstraZeneca since 2008, moving through various role beginning as Director of Strategic Planning before moving onto Country President of AstraZeneca Philippines. He also spent time in the UK, as Global Head of Matured Brands. Prior to roles at AstraZeneca, he had experience working at Baxter and Eli Lilly.

“We are pleased at the appointment of Gagan Singh Bedi as the Managing Director, AstraZeneca Pharma India. Gagan’s expertise and entrepreneurial leadership will be pivotal to the growth of the India business as we continue to strengthen our focus on addressing unmet needs in three main therapy areas – cardiovascular metabolic diseases, respiratory and oncology. We would also like to thank and congratulate Sanjay Murdeshwar for his outstanding contribution to the company and his next assignment in a global role within AstraZeneca,” said Smita Saha, Vice President, HR, AstraZeneca India.

Related Content


AstraZeneca launches health-tech business, Evinova

AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is …

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) …

AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment

AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in …

Latest content